TY - JOUR
T1 - Acute and chronic complications of type 2 diabetes mellitus in children and adolescents
AU - Pinhas-Hamiel, Orit
AU - Zeitler, Philip
PY - 2007/5/26
Y1 - 2007/5/26
N2 - With the increase in prevalence of type 2 diabetes mellitus in adolescents, a rise in incidence of secondary comorbidities-including hypertension, hyperlipidaemia, nephropathy, and retinopathy-is anticipated. Furthermore, findings of studies in young adults have suggested that the development and progression of clinical complications might be especially rapid when the onset of type 2 diabetes is early, raising the possibility of a serious public-health challenge in the next few decades. To date, reports of the epidemiology and natural history of secondary complications specifically in adolescents with type 2 diabetes have been scarce. Yet, we must begin to understand the extent of the coming challenge. To this end, we have reviewed reports on acute and long-term comorbidities associated with type 2 diabetes in young people and have looked at mounting evidence that this group could be at increased risk for development of early complications.
AB - With the increase in prevalence of type 2 diabetes mellitus in adolescents, a rise in incidence of secondary comorbidities-including hypertension, hyperlipidaemia, nephropathy, and retinopathy-is anticipated. Furthermore, findings of studies in young adults have suggested that the development and progression of clinical complications might be especially rapid when the onset of type 2 diabetes is early, raising the possibility of a serious public-health challenge in the next few decades. To date, reports of the epidemiology and natural history of secondary complications specifically in adolescents with type 2 diabetes have been scarce. Yet, we must begin to understand the extent of the coming challenge. To this end, we have reviewed reports on acute and long-term comorbidities associated with type 2 diabetes in young people and have looked at mounting evidence that this group could be at increased risk for development of early complications.
UR - http://www.scopus.com/inward/record.url?scp=34249000034&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(07)60821-6
DO - 10.1016/S0140-6736(07)60821-6
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 17531891
AN - SCOPUS:34249000034
SN - 0140-6736
VL - 369
SP - 1823
EP - 1831
JO - The Lancet
JF - The Lancet
IS - 9575
ER -